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Intragenic CFTR Duplication and 
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Cystic fibrosis (CF) is an autosomal recessive disorder characterized by the accumulation of sticky and 
heavy mucus that can damage several organs. CF shows variable expressivity in affected individuals, but 
it typically causes respiratory and digestive complications as well as congenital bilateral absence of the 
vas deferens in males. Individuals with classic CF usually have variants that produce a defective protein 
from both alleles of the CFTR gene. Individuals with other variants may present with classic, non-classic, 
or milder forms of CF due to lower levels of functional CFTR protein. This article reports the genetic 
analysis of a female with features of asthma and mild or non-classic CF. CFTR sequencing demonstrated 
that she is a carrier for a maternally derived 5T/12TG variant. Deletion/duplication analysis by multiplex 
ligation-dependent probe amplification (MLPA) showed the presence of an intragenic paternally 
derived duplication involving exons 7–11 of the CFTR gene. This duplication is predicted to result in 
the production of a truncated CFTR protein lacking the terminal part of the nucleotide-binding domain 
1 (NBD1) and thus is likely to be a non-functioning allele. The combination of this large intragenic 
duplication and 5T/12TG is the probable cause of the mild or non-classic CF features in this individual.
Cystic fibrosis (CF [MIM 219700]) is an autosomal recessive disorder characterized by the accumulation of sticky 
and heavy mucus that can damage several organs leading to respiratory, digestive, and reproductive system prob-
lems. The disorder, depending on the variant type, can present with nearly 100% penetrance but shows variable 
expressivity in affected individuals, with symptoms including chronic cough, bronchiectasis, bacterial lung infec-
tions, lung and pancreatic fibrosis and insufficiency, poor growth and weight gain, fat soluble vitamin deficiency, 
malabsorptive stools, congenital absence of vas deferens (CAVD) and infertility in males, digital clubbing, and a 
relatively short life span due usually to pulmonary disease and/or liver failure1.
CF diagnosis is performed by a combination of clinical, laboratory, and genetic studies, usually starting with 
sweat chloride testing for symptomatic individuals. Affected individuals have higher amounts of chloride levels in 
their sweat due to an impaired ability to re-uptake chloride ions from their sweat. Abnormal sweat chloride levels 
are suggestive of CF for values equal to or higher than 60 mmol/L. Intermediate levels range from 40 to 59 mmol/L 
for 6-month or older individuals, or 30–59 mmol/L for individuals younger than 6 months of age. Genetic assess-
ment should be performed for individuals with sweat chloride levels higher than 30 mmol/L. CF diagnosis is 
confirmed for symptomatic individuals with abnormal sweat chloride levels and harboring two pathogenic CF 
variants. Overall, CF patients demonstrate different clinical presentations ranging from classic CF to non-classic 
CF. Non-classic or mild CF is a term that is used to describe individuals manifesting with a milder form of CF 
compared to those with classic CF. These individuals usually do not present with pancreatic insufficiency, have 
intermediate sweat chloride levels, do not commonly show progressive lung function decline, and are usually 
diagnosed near adulthood2,3.
The incidence of CF is estimated to be approximately one in 2,500–3,500 for European Americans, one in 
17,000 for African Americans, and one in 31,000 for Asian Americans1. Individuals with CF have pathogenic var-
iants in both alleles of the cystic fibrosis transmembrane conductance regulator gene (CFTR [MIM 602421)]. The 
CFTR gene is located on chromosome 7q31.2, has 27 coding exons, and is the only gene known to be associated 
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with CFTR-related disorders, including CF and CAVD. The CFTR gene encodes a transmembrane channel pro-
tein that transports chloride ions into and out of cells that produce mucus, sweat, saliva, tears, and digestive 
enzymes. CFTR variants that affect the function of the channel can cause extracellular mucus build-up; excessive 
thick and sticky mucus can then obstruct airways of lungs and ducts in the pancreas4.
The most common CFTR variants are single nucleotide substitutions and small deletions and duplica-
tions which may be easily detected by PCR-based techniques; however, large rearrangements have also been 
described5. The most common CFTR pathogenic variant in CF patients worldwide is a deletion of three nucleo-
tides, c.1521_1523delCTT, which encodes part of the first nucleotide-binding domain (NBD1) of the CFTR pro-
tein. This in-frame deletion results in an abnormal CFTR protein that lacks the phenylalanine residue at position 
508 (p.F508del)5–8. Individuals with other variants, including a CF disease-causing variant in trans with a short 
5T nucleotide track and extended 12TG or 13TG di-nucleotide track in the intronic region chr7:117,188,661–
117,188,689 of the CFTR gene, may present with classic, non-classic or milder forms of CF due to potentially 
lower levels of functional CFTR protein9–18.
In this report, we present the case of a female patient with chronic daily cough and sputum production, 
chronic sinusitis, mild reversible airflow obstruction, minimal bronchiectasis, and intermediate sweat chloride 
level, but no pancreatic insufficiency. Clinically, the patient was classified to have features of asthma and mild or 
non-classic CF. Gene sequencing and gene deletion/duplication analyses were performed and revealed the pres-
ence of a maternally derived 5T/12TG variant allele in addition to an intragenic paternally derived duplication 
involving exons 7–11 of the CFTR gene. This duplication is predicted to result in the production of a truncated 
CFTR protein lacking the terminal part of the NBD1 domain and thus is likely a loss of function (LOF) allele7. 
This finding suggest that the combination of this large intragenic duplication and the 5T/12TG variant is the 
probable cause of the mild or non-classic CF features in this individual.
Results
Genetic Analyses of Patient. PCR followed by sequence analysis revealed a c.[1210− 12[5];1210-
34TG[12]] (5T/12TG) allele and a c.[1210− 12[7];1210-34TG[11]] (7T/11TG) allele in the patient DNA (obtained 
from whole blood and buccal swab) (Fig. 1; see parental studies). No other variants were found in the CFTR gene.
Deletion/duplication analysis of the CFTR gene by multiplex ligation-dependent probe amplification (MLPA) 
revealed the presence of an intragenic duplication involving exons 7–11 of the CFTR gene (NM_000492.3), 
which include the minimal region of coordinates chr7:117,176,625–117,199,688 (based on MLPA probe loca-
tion; GRCh37/hg19) (Fig. 2). MLPA results were confirmed using a breakpoint PCR designed by Hantash and 
colleagues to detect a recurrent duplication involving CFTR exons 7–11 (Fig. 3)7.
Parental Studies. Parental buccal swabs were obtained to determine the cis/trans status of the two variants 
identified in our patient. Sanger sequencing and MLPA analysis were performed and revealed that the patient’s 
mother was a carrier for the 5T/12TG allele (Fig. 1) and the patient’s father was a carrier for the intragenic dupli-
cation involving exons 7–11 of the CFTR gene (Fig. 2). The parental MLPA results were further confirmed by 
breakpoint PCR amplification (Fig. 3).
Discussion
In this study, we present the case of a female patient with features of asthma and mild or non-classic CF, who was 
referred for CFTR genetic analyses at our laboratory. The patient was found to have a 5T/12TG allele, in trans 
conformation with an intragenic duplication involving exons 7–11 of the CFTR gene. To our knowledge, this is 
the first CF patient described to have a CFTR intragenic duplication allele along with a 5T track allele. The most 
Figure 1. Sanger sequencing results for T/TG track. Reference DNA T/TG track (top electropherogram) on 
chr7:117,188,661-117,188,689 (GRCh37/hg19) is homozygous 7T; 11TG, or c.[1210− 12[7];1210-34TG[11]]. 
Patient DNA (proband) T/TG track is heterozygous 5T/12TG; 7T/11TG (alleles overlap in figure), father is 
homozygous 7T/11TG, and mother is heterozygous 5T/12TG; 7TG/12TG. F, forward; R, reverse.
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similar case previously reported was that of a Moroccan patient with congenital bilateral absence of the vas def-
erens (CBAVD [MIM 277180]) that had a CFTR heterozygous 5T/12TG in addition to a duplication involving 
exons 12–1419. No information regarding the cis/trans conformation of the two abnormalities was provided.
Previous studies have revealed that the length of the poly-T nucleotide track in intron 9 of the CFTR gene 
affects the levels of CFTR wild-type transcripts containing the adjacent exon (historically labeled exon 9, but 
current nomenclature listed as exon 10 in transcript NM_000492.3), with an individual with a heterozygous 
genotype consisting of a 5T allele and a 7T allele (such as the present case) having significantly reduced wild-type 
CFTR mRNA transcript (approximately 20% of all CFTR transcripts)9,10. Homozygosity for the 5T track has been 
previously reported in a male patient with non-classic CF presenting with sinopulmonary disease and infertility, 
but no history of pancreatitis. The patient genotype was homozygous 5T/11TG in the absence of other CFTR 
mutations after sequencing of all coding regions and splice sites20. Homozygosity for the 5T track has also been 
previously detected in a male patient with recurrent acute pancreatitis and a positive sweat test, but with normal 
respiratory function and urological phenotype. The patient was homozygous for 5T/12TG in the absence of 37 
common European CFTR variants21. Overall, the 5T track, when found in trans conformation with a disease 
causing CF variant or in homozygosity, has been reported in individuals with non-classic CF, infertile males with 
CAVD, and unaffected individuals. The range of phenotype is believed to be related to the variable penetrance of 
the 5T track in causing abnormalities9,22. Furthermore, several studies have supported the idea that the length of 
the poly-TG nucleotide track, which immediately precedes the T track in intron 9 of CFTR, influences the pene-
trance of the 5T genotype; that is, it contributes to the increased levels of transcripts lacking exon 10. Specifically, 
individuals with an allele with a 12TG or 13TG repeat that is in cis with the 5T track (such as the present case) 
have been found to be more likely to show an abnormal clinical presentation than those individuals that had an 
allele with an 11TG repeat in cis with the 5T track14,18,23.
Other than the 5T track in cis with the 12TG track in a CFTR allele, our patient presented with an intragenic 
duplication involving exons 7–11. In order to assess how frequent CFTR duplications overlapping the one found 
in our patient are reported in publicly available data, non-CF databases (including the Coriell Cell Line Copy 
Number Variants, DECIPHER, and the Database of Genomic Variants) were queried but did not reveal any simi-
lar intragenic duplications in the CFTR gene, other than 10 subjects with a CFTR intragenic duplication involving 
exon 10 previously reported as pertaining to a pseudogene or segmental duplication sequence24–31. These data 
Figure 2. CFTR gene MLPA results. Proband and father (not mother) harbor a CFTR intragenic 
duplication involving exons 7, 8, 9, 10, 11 (minimal region of coordinates based on MLPA probe location is 
chr7:117,176,625-117,199,688-GRCh37/hg19). For each individual, the GeneMarker electrophoretograms are 
shown on the left and the normalized MLPA data is shown on the right. The table on the right lists the ratio of 
signal from each MLPA probe from each tested DNA in relation to the combined normal reference controls. A 
ratio of ~1.5 (test/control signal) is indicative of duplication (red squares). Asterisks are showing probes with 
higher ratio indicative of a duplication. The patient’s mother does not carry this duplication.
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suggest that CFTR intragenic duplications involving multiple exons are not common, and further support that 
the duplication found in our patient is likely pathogenic. Furthermore, a large and public CFTR mutation data-
base, Clinical and Functional Translation of CFTR (CFTR2)5, has described 16 alleles with the CFTR duplication 
involving exons 7–11 (reported in the database as CFTRdup6b-10), resulting in an allele frequency of 0.00011 
(relative to a total of 141,341 mutations from 88,664 patients from 41 countries found in the database as of August 
13th, 2015)5. The database reports the duplication as CF-causing with decreased lung function, association with 
pancreatic insufficiency, and average sweat chloride level of 106 mmol/L, but with a wide-range of severity when 
combined with a second CF-causing variant. The patient we describe in this manuscript had mild lung disease, 
no pancreatic insufficiency at the time of assessment, and an intermediate sweat chloride level. This milder phe-
notype in relation to the patients previously described is likely due to the combination of the duplication allele 
(predicted to result in a truncated CFTR protein lacking the terminal part of NBD1, see below) and the 5T/12TG 
allele, both of variable expressivity, and possibly other unknown modifiers5,7,32–34.
Other previously reported cases of CF patients that were found to have intragenic CFTR duplications that 
at least partially overlap exons 7–11 are relatively rare. These patients had classic CFTR mutations in addition 
to intragenic duplications, unlike our patient, who has a CFTR intragenic duplication in addition to a mild var-
iant. As listed below, all these patients were described to have classic CF symptoms, with some reports indi-
cating pancreatic disease and elevated sweat chloride levels. One report was that of a CF French male patient 
diagnosed at three months of age and who died at the age of 31, who had a clinical phenotype that included 
pancreatic insufficiency, severe lung disease, disseminated bronchiechtasis, and an elevated sweat chloride level 
of 90 mmol/L. He had a pathogenic p.G542X variant in addition to a maternally-derived duplication involving 
exons 4–932. A second report was that of a classic CF Italian female patient with a clinical phenotype that included 
recurrent respiratory infections, pancreatic insufficiency, and a sweat chloride level above 100 mmol/L, who had 
a pathogenic maternally-derived p.F508del variant in addition to a paternally-derived duplication involving 
exons 7–1833. This duplication was predicted to result in a truncated CFTR protein. A third report was that of 
Figure 3. Patient and family PCR and Sanger sequencing results. (A) Only the two individuals harboring the 
duplication showed PCR amplification between introns 6 and 11 (upstream junction), while all samples showed 
PCR amplification in intron 11 (downstream junction), as previously reported7. L: ladder; upstream junction 
PCR products from 1: father, 2: mother, 3: proband, 4: blank (water); downstream junction PCR products from 
5: father, 6: mother, 7: proband, 8: blank (water). (B) DNA sequencing electropherograms from the proband and 
her father show intron 11 and intron 6 sequences at the duplication breakpoint, as previously reported7.
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three duplications found from 233 CF chromosomes analyzed from classic CF patients, one involving exons 
1–9, a second involving exons 4–11, and a third involving exons 7–1134. A fourth report was that of a classic CF 
Caucasian female patient with a clinical phenotype that included liver cirrhosis, pulmonary disease and a sweat 
chloride level of 110 mmol/L, who had a sister that reportedly died of CF. The patient was found to have a patho-
genic maternally-derived p.F508del variant in addition to a paternally-derived duplication involving exons 7–11 
(reported in the manuscript as dup6b-10) on a benign 7T/11TG haplotype7. Using DNA sequencing of the dupli-
cation junction fragment, the duplication breakpoint was found to be located in the intronic region surrounding 
the duplicated exons and was predicted to result in a truncated CFTR protein that lacked part of the NBD1 
domain and was considered to be a null allele. The breakpoints were found within repetitive regions which were 
hypothesized to promote the duplication by a non-allelic homologous recombination mechanism. Two other 
unrelated CF Caucasian individuals obtained from another laboratory were reported in the same study, each 
having a pathogenic CFTR variant in addition to the exon 7–11 duplication with the same duplication breakpoint, 
thus suggesting there is likely a founder effect for this duplication7. We performed the breakpoint PCR using the 
primers provided in the aforementioned study and confirmed the same breakpoints flanking the duplication in 
both our patient and her father.
Our genetic analyses suggest that the presence of two mild variants, the 5T/12TG variant in trans with the 
exon 7–11 duplication allele found in the current case, may result in a mild/non-classic CF presentation20,21. 
Interestingly, previous studies have suggested that expression of only 8% of wild-type CFTR mRNA transcripts 
(containing exon 10) from bronchial epithelial cells may be necessary to maintain a normal lung phenotype35. 
Future gene expression studies may be useful to determine the amount of functional CFTR protein produced in 
patients harboring a combination of unusual or mild variants, such as the ones described in our patient. These 
studies may increase our understanding of phenotype/genotype correlations in CF and help the research commu-
nity better define the threshold of wild-type transcripts required for an unaffected CF status. This information will 
then be useful for the development of therapeutic options, for example, using gene therapy strategies.
This case illustrates the importance of searching for variations in the T and TG nucleotide tracks in intron 9, 
as well as large intragenic rearrangements within the CFTR gene in patients with non-classic mild and possibly 
classic CF disease who have an absence of the most commonly found variants (single nucleotide substitutions and 
small indels) in one or both CFTR alleles.
Methods
DNA extraction. Patient whole blood collected in purple-top tube was received at the Indiana University 
Molecular Genetics Diagnostic Laboratory, Indianapolis, IN, and DNA extracted using the Qiagen’s Gentra 
Puregene Blood Kit (Qiagen, Germantown, MD) following the manufacturer’s instructions. Parental and patient 
buccal swabs were collected and received at the Indiana University Molecular Genetics Diagnostic Laboratory, 
Indianapolis, IN, and DNA was extracted using the Qiagen’s Gentra Puregene Blood Kit (Qiagen, Germantown, 
MD) following the manufacturer’s instructions.
Patient clinical information. Informed consent for molecular genetics testing was obtained from the 
patient and her parents. The patient was a 27-year-old female of normal body weight with a history of chronic 
daily cough, sputum production, chronic sinusitis, recurrent lower respiratory tract infections, and intermediate 
sweat chloride levels (58 mmol/L). The patient had no pancreatic insufficiency, no history of malabsorptive stools, 
and no digital clubbing. She was found to have no evidence of wheezing or crackles on lung examination. Her 
pulmonary function tests demonstrated mild airflow obstruction, while high resolution chest imaging showed 
minimal bronchiectasis. Bronchodilator reactivity was not assessed. She was clinically diagnosed to have mild/
non-classic CF with features of asthma. The patient had no family history of CF or other respiratory illnesses.
All methods were carried out in accordance with guidelines and regulations of the Molecular Genetics 
Diagnostic Laboratory at Indiana University. An IRB protocol (protocol # 1401263105) was approved by the 
Human Subjects Office at Indiana University.
PCR and Big Dye Sanger Sequencing. Patient DNA was tested for CFTR coding and splicing vari-
ants in all 27 coding exons, while parental DNA was tested for intron 9T/TG track. Polymerase chain reaction 
(PCR) was performed using HotStar Taq DNA Polymerase kit (Qiagen, Germantown, MD). Briefly, 50 ng of 
genomic DNA was amplified in a 25 μ L reaction that contained 1 μ M of each M13-tailed primer (Integrated DNA 
Technologies, Inc., Coralville, IA; primer sequences are available upon request), 0.2 mM GeneAmp dNTP blend 
(Life Technologies, Carlsbad, CA), 1 mM MgCl2+, 1 unit of HotstarTaq DNA polymerase, and 10x buffer with 
15 mM MgCl2+. Touchdown PCR was performed using the following reaction conditions: 95 °C for 15 min; 14 
cycles of 94 °C for 45 sec, 65 °C for 30 sec with a 0.5 °C decrease per cycle, and 72 °C for 1 min; 24 cycles of 94 °C for 
45 sec, 58 °C for 30 sec, and 72 °C for 1 min; 72 °C for 10 min. PCR products were analyzed using agarose gel elec-
trophoresis to confirm appropriate amplification. Products were then sequenced by automatic fluorescent DNA 
sequencing using an Applied Biosystems (ABI) Prism 3130xl or 3500xl Genetic Analyzer in conjunction with the 
ABI BigDye Terminator v3.1 cycle sequencing kit chemistry and protocol (ABI, Foster City, CA). Sequences were 
analyzed using Mutation Surveyor software V4.0.7 (SoftGenetics, State College, PA) using the CFTR transcript 
NM_000492.3 as reference.
Breakpoint PCR was performed on patient and parental DNA using previously published primer sequences7. 
Briefly, primers Dup6b10upF (5′ -TGTAAAACGACGGCCAGTCAGCATAAGATCCTGAAGGTTTG-3′ ) and 
Dup-6b10upR (5′ -CAGGAAACAGCTATGACCAACACAAAGTAACTAAGGCTCTGGT-3′ ) were used to detect 
the upstream junction fragment, while primers Dup6b10dnF (5′ -TGTAAAACGACGGCCAGTTGG 
CAATGGGGTTGGGAAGT-3 ′  )  and Dup6b10dnR (5 ′  -CAGGAAACAGCTATGACCCTGCTCC 
TCACTATCACAGTCAGTGA-3′ ) were used to detect the downstream junction fragment. PCR, electrophoresis, 
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and sequencing conditions were identical to the ones described above. Sequences were analyzed using Mutation 
Surveyor software V4.0.7, FinchTV software V1.4.0 (Geospiza Inc., Seattle, WA), and the UCSC genome 
browser26 using the CFTR transcript NM_000492.3 as reference.
Multiplex Ligation-Dependent Probe Amplification (MLPA). Patient DNA was tested for CFTR 
exonic deletions and duplications by MLPA following the manufacturer’s instructions for the MLPA P091-D1 
CFTR probemix (MRC-Holland, Amsterdam, Netherlands). This pre-design kit contains probes for all coding 
exons (1–27) of the CFTR gene according to transcript NM_000492.3. Analysis was performed using SoftGenetics 
Gene Marker software v2.6.0 using three normal samples (containing no deletions or duplications within the 
region tested) as references. The normal range for a test sample (no deletion/duplication) is expected to have a 
peak height ratio from 0.8–1.2. The range consistent with a heterozygous deletion for a test sample is expected to 
have a peak height ratio from 0.4–0.6. The range consistent with a heterozygous duplication for a test sample is 
expected to have a peak height ratio from 1.4–2.0.
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